Coronary disease & ACSRandomised controlled trial
Exercise treadmill testing for efficacy evaluation in randomized, controlled trials
- randomized, double-blind, cross-over design
- prespecified analysis
Authors' conclusion
In conclusion, the exercise test has limitations as an objective endpoint of efficacy in randomized trials.
Study context
- Population
- Participants with microvascular angina in the Precision Medicine with Zibotentan in Microvascular Angina trial
- Comparison
- exercise duration was compared across four sequential study visits
- Primary endpoint
- exercise duration
- Follow-up
- 12-weeks
Primary result
As reported in the abstract
- Compared with placebo, zibotentan did not improve exercise duration or angina symptoms
Further findings
Exercise test duration across sequential trial phases · four sequential study visits
- Exercise test duration increased progressively in all participants, independent of treatment with either zibotentan or placebo
Association of improvement in exercise duration with female sex
- effect estimate, female sex
- 34.95 [13.99, 55.78] seconds
- interaction p-value = .0213
- P = .002
- 95% confidence interval
Original publication
Exercise treadmill testing for efficacy evaluation in randomized, controlled trials. Am Heart J. Published 11 February 2026. doi:10.1016/j.ahj.2026.107379
Summarised from the published abstract; every number is checked against it